One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Apellis Pharmaceuticals just hit that mark, with a jump from 77 to 82 Friday.
Risk Management In The Stock Market: How Much Money To Invest Now
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to form a consolidation and break out.
The company posted 0% EPS growth in its most recent report. Sales rose -11%.
Apellis Pharmaceuticals holds the No. 223 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
